Increased vascular endothelial growth factor (VEGF) and transforming growth factorβ (TGF(β)) in experimental autoimmune uveoretinitis: Upregulation of VEGF without neovascularization

Journal of Neuroimmunology

Volumn 89, Issue 1-2, 1998, Pages 43-50

  Vinores, S A ^a   Chan, C C ^b   Vinores, M A ^a   Matteson, D M ^b   Chen, Y S ^a,c   Klein, D A ^a   Shi, A ^a   Ozaki, H ^a   Campochiaro, P A ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b NATIONAL EYE INSTITUTE   (United States)

^c CATHAY GENERAL HOSPITAL   (Taiwan)

Author keywords

Blood retinal barrier; Experimental autoimmune uveoretinitis; Retina; Transforming growth factor beta; Vascular endothelial growth factor

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; BLOOD EYE BARRIER; BLOOD VESSEL PERMEABILITY; CONTROLLED STUDY; FEMALE; IMMUNOHISTOCHEMISTRY; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RAT; RETINA BLOOD VESSEL; RETINA NEOVASCULARIZATION; RETINITIS; UVEITIS; UVEORETINITIS;

ANIMALS; BLOOD-BRAIN BARRIER; ENDOTHELIAL GROWTH FACTORS; EYE PROTEINS; FEMALE; IMMUNIZATION; ISCHEMIA; LYMPHOKINES; MICE; MICE, INBRED STRAINS; NEOVASCULARIZATION, PATHOLOGIC; RATS; RATS, INBRED LEW; RETINA; RETINAL ARTERY; RETINITIS; RETINOL-BINDING PROTEINS; TRANSFORMING GROWTH FACTOR BETA; UP-REGULATION; UVEITIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 18144449167     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(98)00075-7     Document Type: Article

References (59)

1. Adamis A.P., Shima D.T., Yeo K.-T., Yeo T.-K., Brown L.F., Berse B., D'Amore P.A., Folkman J. Synthesis and secretion of vascular permeability factor/vascular endothelial growth factor by human retinal pigment epithelial cells. Biochem. Biophys. Res. Commun. 193:1993;631-638.
2. Adamis A.P., Miller J.W., Bernal M.-T., D'Amico D.J., Folkman J., Yeo T.-K., Yeo K.-T. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am. J. Ophthalmol. 118:1994;445-450.
3. Aiello L.P., Avery R.L., Arrigg P.G., Keyt B.A., Jampel H.D., Shah S.T., Pasquale L.R., Thieme H., Iwamoto M.A., Park J.E., Nguyen H.V., Aiello L.M., Ferrara N., King G.L. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. New Engl. J. Med. 331:1994;1480-1487.
4. Barton K., McLauchlan M.T., Calder V.L., Lightman S. The kinetics of cytokine mRNA expression in the retina during experimental autoimmune uveoretinitis. Cell. Immunol. 164:1995;133-140.
5. Behzadian M.A., Wang X.-L., Jiang B., Caldwell R.B. Angiostatic role of astrocytes: suppression of vascular endothelial cell growth by TGF-β and other inhibitory factor(s). Glia. 15:1995;480-490.
6. Bensaid M., Malecaze F., Bayard F., Tauber J.P. Opposing effects of basic fibroblast growth factor and transforming growth factor-β on the proliferation of cultured bovine retinal capillary endothelial (BREC) cells. Exp. Eye Res. 48:1989;791-799.
7. Border W.A., Noble N.A. Transforming growth factor β in tissue fibrosis. New Engl. J. Med. 331:1994;1286-1292.
8. Caspi R.R., Roberge F.G., Chan C.-C., Wiggert B., Chader G.J., Rosenszajn L.A., Cando Z., Nussenblatt R.B. A new model of autoimmune disease: experimental autoimmune uveoretinitis induced in mice with two different retinal antigens. J. Immunol. 140:1988;1490-1495.
9. Chakravarthy U., Archer D.B. Endothelin: a new vasoactive ocular peptide. Br. J. Ophthalmol. 76:1992;107-108.
10. Chan C.-C., Caspi R.R., Ni M., Leake W.C., Wiggert B., Chader G.J., Nussenblatt R.B. Pathology of experimental autoimmune uveoretinitis in mice. J. Autoimmun. 3:1990;247-255.
11. Chen Y.-S., Hackett S.F., Schoenfeld C.-L., Vinores M.A., Vinores S.A., Campochiaro P.A. Localization of vascular endothelial growth factor and its receptors to cells of vascular and avascular epiretinal membranes. Br. J. Ophthalmol. 81:1997;919-926.
12. Cohen T., Nahari D., Cerem L.W., Neufeld G., Levi B.Z. Interleukin 6 induces the expression of vascular endothelial growth factor. J. Biol. Chem. 271:1996;736-741.
13. Dastgheib K., Li Q., Chan C.-C., Roberge F.G., Csaky K., Green W.R. Vascular endothelial growth factor (VEGF) in neovascular age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 36:1995;S102.
14. DeKozak Y., Sakai J., Thillaye B., Faure J.P. S-antigen-induced experimental autoimmune uveoretinitis in rats. Curr. Eye Res. 1:1981;327-337.
15. DeKozak Y., Naud M.-C., Bellot J., Faure J.-P., Hicks D. Differential tumor necrosis factor expression by resident retinal cells from experimental uveitis-susceptible and -resistant rat strains. J. Neuroimmunol. 55:1994;1-9.
16. Dvorak H.F., Brown L.F., Detmar M., Dvorak A.M. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability and angiogenesis. Am. J. Pathol. 146:1995;1029-1039.
17. Forrester J.V., Liversidge J., Towler H., McMenamin P.G. Comparison of clinical and experimental uveitis. Curr. Eye Res. 9:1990;75-84. Suppl.
18. Forrester J.V., Liversidge J., Dua H.S., Dick A., Harper F., McMenamin P.G. Experimental autoimmune uveoretinitis: a model system for immunomodulation. Curr. Eye Res. 11:1992;33-40. Suppl.
19. Glaser B.M., Campochiaro P.A., Davis J.L., Sato M. Retinal pigment epithelial cells release an inhibitor of neovascularization. Arch. Ophthalmol. 103:1985;1870-1875.
20. Goldberg M.A., Schneider T.J. Similarities between the oxygen-sensing mechanisms regulating the expression of vascular endothelial growth factor and erythropoietin. J. Biol. Chem. 269:1994;4355-4359.
21. Greenwood J. The blood-retinal barrier in experimental autoimmune uveoretinitis (EAU): a review. Curr. Eye Res. 11:1992;25-32.
22. Haddow A. Molecular repair, wound healing, and carcinogenesis: tumor production a possible overhealing? Adv. Cancer Res. 16:1972;181-234.
23. 1 in osteoblasts. J. Clin. Invest. 93:1994;2490-2496.
24. Hashimoto E., Kage K., Ogita T., Nakaoka T., Matsuoka R., Kira Y. Adenosine as an endogenous mediator of hypoxia for induction of vascular endothelial growth factor mRNA in U-937 cells. Biochem. Biophys. Res. Commun. 204:1994;318-324.
25. Jennings J.C., Mohan S., Linkhart T.A., Widstrom R., Bayling K.J. Comparison of the biological activities of TGF-beta 1 and TGF-beta 2: differential activity in endothelial cells. J. Cell Physiol. 137:1988;167-172.
26. Kulkarni A.B., Ward J.M., Yaswen L., Mackall C.L., Bauer S.R., Huh C.-G., Gress R.E., Karlsson S. Transforming growth factor-β1 null mice. An animal model for inflammatory disorders. Am. J. Pathol. 146:1995;264-275.
27. Lehrmann E., Kiefer R., Finsen B., Diemer N.H., Zimmer J., Hartung H.-P. Cytokines in cerebral ischemia: expression of transforming growth factor beta-1 (TGF-β1) mRNA in the postischemic adult rat hippocampus. Exp. Neurol. 131:1995;114-123.
28. Lightman S., Greenwood J. Effect of lymphocytic infiltration on the blood-retinal barrier in experimental autoimmune uveoretinitis. Clin. Exp. Immunol. 88:1992;473-477.
29. Luna J.D., Chan C.-C., Derevjanik N.L., Mahlow J., Chiu C., Peng B., Tobe T., Campochiaro P.A., Vinores S.A. Blood-retinal barrier (BRB) breakdown in experimental autoimmune uveoretinitis: Comparison with vascular endothelial growth factor, tumor necrosis factor α, and interleukin-1β-mediated breakdown. J. Neurosci. Res. 49:1997;268-280.
30. Lutty G.A., McLeod D.S., Merges C., Diggs A., Plouet J. Localization of vascular endothelial growth factor in human retina and choroid. Arch. Ophthalmol. 114:1996;971-977.
31. Mahalak S.M., Lin W.-L., Essner E., Shichi H. Increased immunoreactivity of collagen types I, III and V, fibronectin- and TGF-β in retinal vessels of rats with experimental autoimmune uveoretinitis. Curr. Eye Res. 10:1991;1059-1063.
32. Malecaze F., Clamens S., Simorre-Pinatel V., Mathis A., Chollet P., Favard C., Bayard F., Plouet J. Detection of vascular endothelial growth factor messenger RNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy. Arch. Ophthalmol. 112:1994;1476-1482.
33. Mandriota S.J., Menoud P.A., Pepper M.S. Transforming growth factor β1 down-regulates vascular endothelial growth factor receptor 2/flk-1 expression in vascular endothelial cells. J. Biol. Chem. 271:1996;11500-11505.
34. McAvoy, J., Chamberlain, C.G. Growth factors in the eye. In: Progress in Growth Factor Research, Vol. 2. Pergamon, 1990, pp. 29-43.
35. McMenamin P.G., Broekhuyse R.M., Forrester J.V. Ultrastructural pathology of experimental autoimmune uveitis: a review. Micron. 24:1993;521-546.
36. McMenamin P.G., Forrester J.V., Steptoe R., Dua H.S. Ultrastructural pathology of experimental autoimmune uveitis in the rat. Autoimmunity. 16:1993;83-93.
37. Miller J.W., Adamis A.P., Shima D.T., D'Amore P.A., Moulton R.S., O'Reilly M.S., Folkman J., Dvorak H.F., Brown L.F., Berse B., Yeo T.-K., Yeo K.-T. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am. J. Pathol. 145:1994;574-584.
38. Minchenko A., Bauer T., Salceda S., Caro J. Hypoxic stimulation of vascular endothelial growth factor expression in vitro and in vivo. Lab. Invest. 71:1994;374-379.
39. Minchenko A., Salceda S., Bauer T., Caro J. Hypoxia regulatory elements of the human vascular endothelial growth factor gene. Cell. Mol. Biol. Res. 40:1994;35-39.
40. Nussenblatt R.B., Gery I. Experimental autoimmune uveitis and its relationship to clinical ocular inflammatory disease. J. Autoimmun. 9:1996;575-585.
41. Ozaki H., Hayashi H., Vinores S.A., Moromisato Y., Campochiaro P.A., Ohshima K. Intravitreal sustained release of VEGF causes retinal neovascularization in rabbits and breakdown of the blood-retinal barrier in rabbits and primates. Exp. Eye Res. 64:1997;505-517.
42. Penn J.S., Tolman B.L., Lowery L.A. Variable oxygen exposure causes preretinal neovascularization in the newborn rat. Invest. Ophthalmol. Vis. Sci. 34:1993;576-585.
43. Penn J.S., Tolman B.L., Henry M.M. Oxygen-induced retinopathy in the rat: relationship of retinal nonperfusion to subsequent neovascularization. Invest. Ophthalmol. Vis. Sci. 35:1994;3429-3435.
44. Pertovaara L., Kaipainen A., Mustonen T., Orpana A., Ferrara N., Saksela O., Alitalo K. Vascular endothelial growth factor is induced in response to transforming growth factor-β in fibroblastic and epithelial cells. J. Biol. Chem. 269:1994;6271-6274.
45. Pierce E.A., Avery R.L., Foley E.D., Aiello L.P., Smith L.E.H. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc. Natl. Acad. Sci. U.S.A. 92:1995;905-909.
46. Plate K.H., Breier G., Millauer B., Ullrich A., Risau W. Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. Cancer Res. 53:1993;5822-5827.
47. Rajasingh J., Singh V.K., Singh V., Sharma K., Agarwal S.S. Cellular immune response to retinal S-antigen and interphotoreceptor retinoid binding protein fragments in idiopathic human uveitis. Indian J. Med. Res. 103:1966;222-226.
48. Ramanthan S., DeKozak Y., Saoudi A., Goureau O., van der Meide P.H., Druet P., Bellow B. Recombinant IL-4 aggravates experimental autoimmune uveoretinitis. J. Immunol. 157:1996;2209-2215.
49. Roberts, A.B., Sporn, M.B. The transforming growth factor-βs. In: Sporn, M.B., Roberts, A.B. (Eds.), Peptide Growth Factors and their Receptors I. Springer-Verlag, New York, 1990, pp. 419-472.
50. Sato Y., Rifkin D.B. Inhibition of endothelial cell movement by pericytes and smooth muscle cells: activation of a latent transforming growth factor β1 like molecule by plasmin during co-culture. J. Cell. Biol. 109:1989;309-315.
51. Senger D.R., Galli S.J., Dvorak A.M., Perruzzi C.A., Harvey V.S., Dvorak H.F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 219:1983;983-985.
52. Senger D.R., Perruzzi C.A., Feder J., Dvorak H.F. A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res. 46:1986;5629-5632.
53. Senger D.R., van de Water L., Brown L.F., Nagy J.A., Yeo K.-T., Yeo T.-K., Berse B., Jackman R.W., Dvorak A.M., Dvorak H.F. Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev. 12:1993;303-324.
54. Shima D.T., D'Amore P.A. Molecular mechanisms of hypoxic regulation of vascular endothelial growth factor (VEGF). Invest. Ophthalmol. Vis. Sci. 36:1995;S870.
55. Sun B., Rizzo L.V., Sun S.-H., Chan C.-C., Wiggert B., Wilder R.L., Caspi R.R. Genetic susceptibility to experimental autoimmune uveitis involves more than a predisposition to generate a T helper-1-like or a T helper-2-like response. J. Immunol. 159:1997;1004-1011.
56. Tolentino M.J., Miller J.W., Gragoudas E.S., Jakobiec F.A., Flynn E., Chatzistefanou K., Ferrara N., Adamis A.P. Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology. 103:1996;1820-1828.
57. Vinores S.A., Küchle M., Mahlow J., Chiu C., Green W.R., Campochiaro P.A. Blood-ocular barrier breakdown in eyes with ocular melanoma: a potential role for vascular endothelial growth factor/vascular permeability factor. Am. J. Pathol. 147:1995;1289-1297.
58. Vinores S.A., Youssri A.I., Luna J.D., Chen Y.-S., Bhargave S., Vinores M.A., Schoenfeld C.-L., Peng B., Chan C.-C., LaRochelle W., Green W.R., Campochiaro P.A. Upregulation of vascular endothelial growth factor in ischemic and non-ischemic human and experimental retinal disease. Histol. Histopathol. 12:1997;99-109.
59. Yoshimura N., Matsumoto M., Shimizu H., Mandai M., Hata Y., Ishibashi T. Photocoagulated human retinal pigment epithelial cells produce an inhibitor of vascular endothelial cell proliferation. Invest. Ophthalmol. Vis. Sci. 36:1995;1686-1691.